Identifying therapeutic vulnerabilities in fibrolamellar carcinoma

Timeframe: 2020 – 2023 Goal: Investigate the impact on FLC growth and survival of inhibiting two specific oncogenes identified in previous works Principal Investigator: Praveen Sethupathy Associate Professor Department of Biomedical Sciences, Cornell University, College of Veterinary Medicine Based on previous epigenomic, metabolomic, and microRNA profiling, as well as initial drug studies, the study team …

Read more

Multicenter consortium to define the single-cell activity landscape of fibrolamellar carcinoma.

Timeframe: 2022 – 2024 Goal: Advance immunotherapy for FLC, by defining the most promising immunological targets that can be translated into effective cell-based immunotherapies Principal Investigators: Praveen Sethupathy, PhD, Biomedical Sciences, Cornell University; Mark Yarchoan, MD, Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Paul G. Thomas, PhD, Immunology, St. Jude Children’s Research Hospital …

Read more

Micro RNAs and long non-coding RNAs role in fibrolamellar and evaluation of RNA-based therapeutics

Timeframe: 2017 – 2020 Goal: Investigate the role of microRNAs and long non-coding RNAs in fibrolamellar carcinoma and evaluate RNA-based therapeutics Principal Investigator: Praveen Sethupathy Associate Professor Department of Biomedical Sciences, Cornell University, College of Veterinary Medicine This study aimed to leverage genome-scale approaches to discover the molecular factors most critical to FLC tumor formation, …

Read more

Retinoic acid-induced loss of DNAJB1-PRKACA fusion protein expression

Timeframe: 2019-2022 Goal: Investigate the potential of retinoic acid therapy Principal Investigator: Andrew Yen, PhD, Professor, Department of Biomedical Sciences Co-Principal Investigator: Praveen Sethupathy, PhD, Associate Professor, Department of Biomedical Sciences FLC is driven by the DNAJ-PKAc fusion protein. A potential therapeutic strategy would be to induce loss of this key driver protein. One approach …

Read more